TY - JOUR
T1 - The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia
AU - Kim, Eric H.
AU - Brockman, John A.
AU - Andriole, Gerald L.
N1 - Publisher Copyright:
© 2018 Editorial Office of Asian Journal of Urology
PY - 2018/1
Y1 - 2018/1
N2 - Benign prostatic hyperplasia (BPH)is characterized by an enlarged prostate, lower urinary tract symptoms (LUTS), and a decreased urinary flow rate. Common in older men, BPH is a progressive disease that can eventually lead to complications including acute urinary retention (AUR)and the need for BPH-related surgery. Both normal and abnormal prostate growth is driven by the androgen dihydrotestosterone (DHT), which is formed from testosterone under the influence of 5-alpha reductase. Thus, 5-alpha reductase inhibitors (5-ARIs)effectively reduce the serum and intraprostatic concentration of DHT, causing an involution of prostate tissue. Two 5-ARIs are currently available for the treatment of BPH—finasteride and dutasteride. Both have been demonstrated to decrease prostate volume, improve LUTS and urinary flow rates, which ultimately reduces the risk of AUR and BPH-related surgery. Therefore, either alone or in combination with other BPH medications, 5-ARIs are a mainstay of BPH management.
AB - Benign prostatic hyperplasia (BPH)is characterized by an enlarged prostate, lower urinary tract symptoms (LUTS), and a decreased urinary flow rate. Common in older men, BPH is a progressive disease that can eventually lead to complications including acute urinary retention (AUR)and the need for BPH-related surgery. Both normal and abnormal prostate growth is driven by the androgen dihydrotestosterone (DHT), which is formed from testosterone under the influence of 5-alpha reductase. Thus, 5-alpha reductase inhibitors (5-ARIs)effectively reduce the serum and intraprostatic concentration of DHT, causing an involution of prostate tissue. Two 5-ARIs are currently available for the treatment of BPH—finasteride and dutasteride. Both have been demonstrated to decrease prostate volume, improve LUTS and urinary flow rates, which ultimately reduces the risk of AUR and BPH-related surgery. Therefore, either alone or in combination with other BPH medications, 5-ARIs are a mainstay of BPH management.
KW - 5-alpha reductase inhibitors
KW - Benign prostatic hyperplasia
KW - Lower urinary tract symptoms
UR - http://www.scopus.com/inward/record.url?scp=85038867766&partnerID=8YFLogxK
U2 - 10.1016/j.ajur.2017.11.005
DO - 10.1016/j.ajur.2017.11.005
M3 - Review article
C2 - 29379733
AN - SCOPUS:85038867766
SN - 2214-3882
VL - 5
SP - 28
EP - 32
JO - Asian Journal of Urology
JF - Asian Journal of Urology
IS - 1
ER -